370 related articles for article (PubMed ID: 21770405)
1. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
2. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
3. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer.
Zhang X; Gan Y; Gan L; Nie S; Pan W
J Pharm Pharmacol; 2008 Aug; 60(8):1077-87. PubMed ID: 18644200
[TBL] [Abstract][Full Text] [Related]
4. Octreotide-modified and pH-triggering polymeric micelles loaded with doxorubicin for tumor targeting delivery.
Niu J; Su Z; Xiao Y; Huang A; Li H; Bao X; Li S; Chen Y; Sun M; Ping Q
Eur J Pharm Sci; 2012 Jan; 45(1-2):216-26. PubMed ID: 22119655
[TBL] [Abstract][Full Text] [Related]
5. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
[TBL] [Abstract][Full Text] [Related]
6. [Preparation of PEG-modified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice].
Zhang XX; Gan Y; Yang XG; Zhu CL; Gan L; Nie SF; Pan WS
Yao Xue Xue Bao; 2008 Jan; 43(1):91-6. PubMed ID: 18357740
[TBL] [Abstract][Full Text] [Related]
7. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
[TBL] [Abstract][Full Text] [Related]
8. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
Zhang S; Wang J; Pan J
Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.
Jia L; Shen J; Zhang D; Duan C; Liu G; Zheng D; Tian X; Liu Y; Zhang Q
Int J Biol Macromol; 2012 Apr; 50(3):523-9. PubMed ID: 22301003
[TBL] [Abstract][Full Text] [Related]
10. Nanostructured lipid carriers loaded with simvastatin: effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity.
Safwat S; Ishak RAH; Hathout RM; Mortada ND
Drug Dev Ind Pharm; 2017 Jul; 43(7):1112-1125. PubMed ID: 28276784
[TBL] [Abstract][Full Text] [Related]
11. PEGylated long circulating nanostructured lipid carriers for Amoitone B: preparation, cytotoxicity and intracellular uptake.
Luan J; Yang X; Chu L; Xi Y; Zhai G
J Colloid Interface Sci; 2014 Aug; 428():49-56. PubMed ID: 24910034
[TBL] [Abstract][Full Text] [Related]
12. pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation.
Kim CH; Sa CK; Goh MS; Lee ES; Kang TH; Yoon HY; Battogtokh G; Ko YT; Choi YW
Int J Nanomedicine; 2018; 13():6661-6675. PubMed ID: 30425481
[TBL] [Abstract][Full Text] [Related]
13. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying.
Zhang X; Pan W; Gan L; Zhu C; Gan Y; Nie S
Chem Pharm Bull (Tokyo); 2008 Dec; 56(12):1645-50. PubMed ID: 19043233
[TBL] [Abstract][Full Text] [Related]
14. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier.
Niu J; Huang A; Xiao Y; Su Z; Li H; Ping Q; Bao X; Li S; Chen Y; Sun M
J Drug Target; 2013 May; 21(5):415-26. PubMed ID: 23597028
[TBL] [Abstract][Full Text] [Related]
15. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
16. Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy.
Zhang G; Liu F; Jia E; Jia L; Zhang Y
Drug Deliv; 2016 May; 23(4):1393-7. PubMed ID: 26165422
[TBL] [Abstract][Full Text] [Related]
17. Redox sensitive PEG controlled octaarginine and targeting peptide co-modified nanostructured lipid carriers for enhanced tumour penetrating and targeting in vitro and in vivo.
Wang H; Sun M; Li D; Yang X; Han C; Pan W
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):313-322. PubMed ID: 28362124
[TBL] [Abstract][Full Text] [Related]
18. [9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo].
Li JC; Sha XY; Zhang LJ; Fang XL
Yao Xue Xue Bao; 2005 Nov; 40(11):970-5. PubMed ID: 16499078
[TBL] [Abstract][Full Text] [Related]
19. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
20. Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors.
Banerjee P; Geng T; Mahanty A; Li T; Zong L; Wang B
Int J Pharm; 2019 Feb; 557():374-389. PubMed ID: 30610896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
